Novo Nordisk Has Probably Declined Enough
Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...
As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.
Morningstar4d
Novo Nordisk sales beat estimates, but the story wasn't Ozempic
Novo Nordisk said its fourth-quarter profit rose ... We sell different types of products and services to both investment professionals and individual investors. These products and services are ...
KAAL TV12d
Novo Nordisk insulin now $35 per month for Minnesotans thanks to Attorney General Keith Ellison
Attorney General Keith Ellison announced a settlement with Novo Nordisk that let's Minnesotans buy its insulin products for ...